Abstract:A link between Down's syndrome (DS) and Alzheimer disease (AD) is widely recognized. Most individuals with DS will manifest AD by the age of 50. Trisomy 21 results in a 4 to 5-fold increase in expression of the APP gene and accelerated deposition of β-amyloid. Compared to normal controls (NCs), brain imaging studies in late-onset AD (LOAD) have demonstrated increased fibrillar β-amyloid binding and a characteristic and progressive pattern of regional reductions in glucose metabolism and gray matter volume. This study aimed to assess the difference of the measures based on these 3 neuroimaging modalities amongyoung/old DS, DS-with dementia (DSWD), and NC subjects. There were 9 NC (3F, 6M) participants, 12 DS (7F, 5M) participants without dementia, and 5 DSWD (3F, 2M) participants, all consented or assented depending on established capacity. Of the 26 participants enrolled and obtained cognitive testing, 24 participants underwent volumetric MRI, florbetapir PET and FDG-PET. Comparing among the 3 group, DSWD vs. age-matched old DS (n=5) and DSWD vs. young DS (n=5), SPM8 was used for voxel-wise data analysis (FDG, MRI and florbetapir) and predefined regions of interest (ROI) analysis including mean cortical ROI (florbetapir). SUVRs (standard uptake value ratios) for florbetapir data were calculated using pontine as the reference region. Mean cortical-to-pontne florbetapir ROI SUVRs were significantly higher in DSWD subjects than in DS and than in NCs (ANOVA with linear trend) (NC=1.15±0.06, DS=1.27±0.09 and DSWD=1.54±0.21p=0.00002), a findings also confirmed in voxel-wise analysis (p=0.0 01 uncorrected). When compared to age matched DS and young DS patients separately, reductions) in .DSWD patients were observed in temporal-parietal lobes, frontal, and occipital regions known to be preferentially affected by LOAD in terms of both the regional to whole brain metabolism and the regional gray matter (uncorrected P=0.001. Additional frontal reductions were also observed when compared to the young DS subjects. In comparison with DS patients and NCs, DSWD subjects have significantly greater fibrillar Aβ burden, as well as significantly lower glucose metabolism and gray matter volume in AD-affected regions, similar to that observed in LOAD. Additional studies are needed to expand our samples, track these changes over time, and provide sample size estimates for clinical and preclinical AD trials in patients with DS.

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein

Common genetic signatures of Alzheimer's disease in Down Syndrome

A Common Link Between Alzheimer's Disease and Down Syndrome

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose

A Novel Mechanism Underlying Pathogenesis of Down Syndrome

Frontal Cortex and Striatal Cellular and Molecular Pathobiology in Individuals with Down Syndrome with and Without Dementia

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Untangle the mystery behind DS-associated AD - Is APP the main protagonist?

APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons

Alzheimer’s drugs, APPlication for Down syndrome?

Age-Related Neurodegeneration and Memory Loss in Down Syndrome

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration.

Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.

Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome

Does the Timing of Alzheimer’s Disease vary by Severity of Intellectual Disability in Down Syndrome?

Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome

Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics

Florbetapir PET, FDG-PET and MRI in People with Down Syndrome with and Without Symptomatic Alzheimer's Disease

Amyloid-β Precursor Protein Facilitates the Regulator of Calcineurin 1-Mediated Apoptosis by Downregulating Proteasome Subunit Α Type-5 and Proteasome Subunit Β Type-7.